The Australian Immunisation Handbook 10th Edition

1 August 2016

Page last updated: 01 August 2017

1 August 2016

Key updates made to the 10th edition Handbook in August 2016 are listed below by chapter, including chapter sections and subsections. Other minor amendments to those listed below have been made to improve clarity, consistency and accuracy; these changes are not specifically noted. References have been removed, updated or introduced where required.

Note: The updated chapter is available online only in HTML formats.

Chapter 2.1 Pre-vaccination

  • Updated information on Australia’s immunisation registers to align with the Australian Immunisation Register Act 2015.
  • Update in line with A New Tax System (Family assistance) Act 1999:
    • New text updated criteria for eligibility for a medical exemption to vaccination based on natural immunity.
    • Table 2.1.12 Catch-up schedule for persons ≥10 years of age to clarify pertussis catch-up recommendations.

Chapter 2.2 Administration of vaccines

  • Aligning with the advice in the Australian Guidelines for the Prevention and Control of Infection in Healthcare (2010).

Chapter 2.3 Post-vaccination

  • Updated information on Australia’s immunisation registers to align with the Australian Immunisation Register Act 2015.
  • Update to publication timelines for aggregate Therapeutic Goods Administration (TGA) vaccine Adverse Effects Following Immunisation reports in Communicable Diseases Intelligence (CDI).

Chapter 3.2 Vaccination for international travel

  • Updated ATAGI advice on 10-yearly booster dose requirements for yellow fever, as well as required updates to supporting data and resources for travel vaccination. Refer also to the Yellow fever chapter.

Chapter 3.3 Groups with special vaccination requirements

  • Clarification of advice on the administration of live vaccines to patients who are immunocompromised, including specific advice on biological and non-biological disease modifying anti-rheumatic drugs (DMARDs).
  • Relevant changes to align with new updates in other chapters (i.e. Influenza, Pneumococcal and Yellow fever).

Chapter 4.12 Pertussis (also chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.5 Hepatitis B, 4.14 Poliomyelitis and 4.19 Tetanus, as required)

  • Clarification of advice, including:
    • On those who are considered close contacts of young infants and those who are considered contacts of others at increased risk from pertussis.
    • On the appropriate action if the dose of dTpa recommended during pregnancy is administered before the third trimester.
    • On the appropriate action for future pertussis vaccines when a mother receives a dose of dTpa post-partum rather than in the third trimester of pregnancy.
    • On the recommended interval between DT-containing vaccines in two contexts: a) standard catch-up and b) maternal pertussis vaccination.
    • That a history of extensive limb swelling after a booster dose of DTPa is not a contraindication to future recommended doses of pertussis-containing vaccine.
  • Factual changes to chapter/s, including:
    • Addition of combination pertussis-containing vaccine, Hexaxim, to the vaccine information box.
    • Updates to Product Information.

Chapter 4.6 Human papillomavirus

  • New text noting alternative schedule for 2vHPV in adolescent girls recently registered by the TGA (no change to ATAGI recommendation at this stage).

Chapter 4.13 Pneumococcal disease

  • Clarification of advice on the co-administration of trivalent influenza vaccines and 13-valent pneumococcal conjugate vaccines in children, in alignment with update to the Influenza chapter (including new reference).
  • Clarification of advice on pneumococcal vaccination during pregnancy and breastfeeding.

Chapter 4.20 Tuberculosis

  • New text advising on the event of a shortage of the currently registered BCG vaccine and usage of alternative vaccine products.
  • New sub-section providing advice on the co-administration of BCG vaccine with other vaccines.
  • New sub-section providing advice on BCG vaccination before or after immunoglobulin or blood product administration.

Chapter 4.23 Yellow fever (Category II update – went out to public consultation)

  • Updated ATAGI advice that 10-yearly booster doses are no longer routinely recommended except for groups/circumstances who are specified.
  • Clarification of advice, including:
    • On the co-administration of yellow fever vaccine with other parenteral live vaccines.
    • On circumstances when vaccination can be considered for pregnant and breastfeeding women.
    • Of groups for whom yellow fever vaccination is contraindicated and appropriate mosquito avoidance advice for such individuals.
    • On the vaccine requirements that need to be meet under updated International Health Regulations (both in Australia and internationally).

Chapter 4.24 Zoster

  • Clarification of advice on the administration of live vaccines to patients receiving or planning treatment with biological and non-biological disease modifying anti-rheumatic drugs (DMARDs).
  • Removal of sub-section providing advice on the co-administration of zoster vaccine with other vaccines as information already provided earlier in chapter.